UBS AM
HUMA icon

UBS AM’s Humacyte HUMA Stock Holding History

UBS AM’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-242,616
Closed -$414K – 2665
2025
Q1 		$414K Buy
242,616
+39,791
+20% +$149K ﹤0.01% 2529
2024
Q4 		$1.02M Buy
202,825
+93,283
+85% +$462K ﹤0.01% 2351
2024
Q3 		$596K Buy
+109,542
New +$722K ﹤0.01% 2600
2022
Q3 		– Sell
-15,947
Closed -$51.2K – 2757
2022
Q2 		$51.2K Buy
15,947
+2,347
+17% +$13K ﹤0.01% 2670
2022
Q1 		$96K Hold
13,600
– – ﹤0.01% 2742
2021
Q4 		$98.6K Buy
+13,600
New +$135K ﹤0.01% 2821

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS AM's HUMA Position: Q2 2025 in Review

UBS AM sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 242,616 shares — an estimated $414K sold.

UBS AM first reported a position in HUMA in Q4 2021 and held it in 6 quarters. The position peaked at $1.02M in Q4 2024. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

  • UBS AM reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
  • UBS AM sold 242,616 Humacyte shares in Q2 2025, an estimated $414K.
  • UBS AM first reported a position in Humacyte in Q4 2021 and held it in 6 quarters.
  • UBS AM's Humacyte position peaked at $1.02M in Q4 2024.
  • 156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.